Background: Contrast-induced acute kidney injury (CI-AKI) is the third most common cause of AKI in hospitalized patients. Contrast agents mainly cause acute kidney injury through hypoxic damage to renal parenchyma and...Background: Contrast-induced acute kidney injury (CI-AKI) is the third most common cause of AKI in hospitalized patients. Contrast agents mainly cause acute kidney injury through hypoxic damage to renal parenchyma and toxic effects on renal capillaries and tubules. Patients with CI-AKI are more likely to experience adverse events, including longer hospital stay and costs, longer ICU stay, and higher mortality rates. This article elaborates on the definition, epidemiology, risk factors, pathogenesis, and prevention strategies of CI-AKI. Methods: We conducted an extensive literature search using contrast agents and AKI as keywords to identify relevant studies on CI-AKI. Conclusion: CI-AKI is a significant clinical challenge that requires a multifaceted approach to prevention and management. Understanding the risk factors, pathophysiology, and current best practices is essential for healthcare providers to optimize patient care and improve outcomes in those undergoing contrast-enhanced imaging procedures. Hydration therapy is currently the main prevention method, but antioxidants may also become a new strategy.展开更多
Background: Chronic kidney disease patients are at a greater risk for nephropathy requiring dialysis after percutaneous coronary intervention. Such patients are usually deferred due to fear of “Renalism”.?Objectives...Background: Chronic kidney disease patients are at a greater risk for nephropathy requiring dialysis after percutaneous coronary intervention. Such patients are usually deferred due to fear of “Renalism”.?Objectives This study assesses the outcome of Low dose contrast protocol during PCI in CKD patients whose e-GFR 60 ml/min/1.72 m and investigates a safety margin for contrast use in these high-risk categories.?Methods: Patients were into three groups according to CV/e-GFR ratio: Group (A) low-dose: CV/e-GFR ratio 2.0 Group (B) medium-dose: CV/e-GFR ratio > 2.0 and × bodyweight\s.creatinine). Group (C) high-dose: CV/e-GFR ratio > MACD. Results: A total of 73 patients were enrolled. Average age was 54 ± 8 years,81.4% were male and 18.6% were females and 52% were diabetic. Mean baseline e-GFR was 40 ± 8.0 ml/min/1.73m2. Contrast Volume used in group A was (58.26 ± 15.05) (n = 24), in group B (109.42 ± 17.11) (n = 26) and in group C (304.5 ± 60.30) (n = 23), respectively. The incidences of CI-AKI in the 3 groups were 0%, 11.5% and 35%, respectively (p = 0.02). All-cause death 0%, 17% and introduction of maintenance hemo dialysis was 0%, 11.5% and 26%, respectively (p Conclusion: Low dose contrast protocol is safe, effective and easily applicable technique without CI-AKI or death.展开更多
文摘Background: Contrast-induced acute kidney injury (CI-AKI) is the third most common cause of AKI in hospitalized patients. Contrast agents mainly cause acute kidney injury through hypoxic damage to renal parenchyma and toxic effects on renal capillaries and tubules. Patients with CI-AKI are more likely to experience adverse events, including longer hospital stay and costs, longer ICU stay, and higher mortality rates. This article elaborates on the definition, epidemiology, risk factors, pathogenesis, and prevention strategies of CI-AKI. Methods: We conducted an extensive literature search using contrast agents and AKI as keywords to identify relevant studies on CI-AKI. Conclusion: CI-AKI is a significant clinical challenge that requires a multifaceted approach to prevention and management. Understanding the risk factors, pathophysiology, and current best practices is essential for healthcare providers to optimize patient care and improve outcomes in those undergoing contrast-enhanced imaging procedures. Hydration therapy is currently the main prevention method, but antioxidants may also become a new strategy.
文摘Background: Chronic kidney disease patients are at a greater risk for nephropathy requiring dialysis after percutaneous coronary intervention. Such patients are usually deferred due to fear of “Renalism”.?Objectives This study assesses the outcome of Low dose contrast protocol during PCI in CKD patients whose e-GFR 60 ml/min/1.72 m and investigates a safety margin for contrast use in these high-risk categories.?Methods: Patients were into three groups according to CV/e-GFR ratio: Group (A) low-dose: CV/e-GFR ratio 2.0 Group (B) medium-dose: CV/e-GFR ratio > 2.0 and × bodyweight\s.creatinine). Group (C) high-dose: CV/e-GFR ratio > MACD. Results: A total of 73 patients were enrolled. Average age was 54 ± 8 years,81.4% were male and 18.6% were females and 52% were diabetic. Mean baseline e-GFR was 40 ± 8.0 ml/min/1.73m2. Contrast Volume used in group A was (58.26 ± 15.05) (n = 24), in group B (109.42 ± 17.11) (n = 26) and in group C (304.5 ± 60.30) (n = 23), respectively. The incidences of CI-AKI in the 3 groups were 0%, 11.5% and 35%, respectively (p = 0.02). All-cause death 0%, 17% and introduction of maintenance hemo dialysis was 0%, 11.5% and 26%, respectively (p Conclusion: Low dose contrast protocol is safe, effective and easily applicable technique without CI-AKI or death.
